CymaBay Therapeutics, Inc.

There have been numerous deals centered on metabolic dysfunction-associated steatohepatitis (MASH) over roughly the past decade, but the 14 May deal in which GSK acquired Boston Pharmaceuticals’ Phase

Ipsen is making good progress in reducing its reliance on the acromegaly and neuroendocrine tumour blockbuster Somatuline, according to CEO David Loew who has heralded the launches of two rare disease

In Vivo ’s editors, along with experts from the Citeline team, selected four top picks for the most significant M&A, alliance and financing deals of 2022. The public votes have been counted and it

Gilead Sciences has worked for decades to build a dominant presence in HIV treatment and prevention, but the company is only years into its buildout of an oncology portfolio, with even more work to do